Studies have shown that SLC7A11 has a prevalent expression level in various cancers, and its elevated expression may hinder ROS-triggered ferroptosis, encourage tumor expansion, and foster resistance to medication (Benedetti, Jézéquel & Orlandi, 1988; He et al., 2023a; Jiang et al., 2015; Park et al., 2010; Wang et al., 2017). Here, SLC7A11 is linked to cancer.